RudaCure es una startup biofarmacéutica en etapa clínica founded in 2018 and based in South Korea that está desarrollando medicines for incurable diseases based on the most advanced life-science technologies to help improve human lives. By developing tratamiento techniques for intractable and incurable diseases, RudaCure will solve its unmet needs and treat the physical and mental pain for pacientes suffering from them. With creative pharmaceutical desarrollo and biomedical investigación, RudaCure is on the path to grow into a empresa farmacéutica global.
Current main products in desarrollo include RCI001 for enfermedad de ojo seco, which is in pre-IND phase and awaiting to start Phase 2 FDA ensayo clínicos el próximo año. RudaCure also plan to secure additional indications for RCI001 including conjunctivitis, keratitis and úlcera corneals. Second in desarrollo is RCI002, which is a non-opioid tratamiento for neuropathic and dolor crónico currently in optimization stage. Other early stage products in desarrollo include tratamientos for atopic dermatitis, metastasis and CRPS.
Since April of 2021, RudaCure has successfully licensed-out RCI001 to Hanlim Pharm for nacional rights in a $12 million deal, and actualmente está looking for more inversores and partners to licenciamiento for internacional mercados. Helping RudaCure along the way, are start-up accelerators MassChallenge and Shinhan Square Bridge, which are both helping RudaCure enter the US mercado.